Toward better vaccine safety data and safer vaccination

Pediatrics

Volumn 121, Issue 3, 2008, Pages 625-626

  Miles Braun, M ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; ROTAVIRUS VACCINE;

AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLEEDING; BRAIN HEMORRHAGE; CHILD; CHILDHOOD DISEASE; DISEASE ASSOCIATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNIZATION; INSULIN DEPENDENT DIABETES MELLITUS; INTUSSUSCEPTION; MAJOR CLINICAL STUDY; MEASLES; MENINGOCOCCOSIS; MULTIPLE SCLEROSIS; MUMPS; NOTE; PERTUSSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RUBELLA; SEIZURE; THROMBOCYTOPENIA; VACCINATION; VIRUS INFECTION; DRUG SURVEILLANCE PROGRAM; DRUG TOXICITY; FEMALE; INFANT; MALE; METHODOLOGY; PRESCHOOL CHILD; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; THROMBOCYTOPENIC PURPURA; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; PURPURA, THROMBOCYTOPENIC; RISK ASSESSMENT; UNITED STATES; VACCINATION;

EID: 40949127452     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-3846     Document Type: Note

References (18)

1. Institute of Medicine. Measles and mumps vaccines. In: Strat- ton KR, Howe CJ, Johnston RB, eds. Adverse Events Associated With Childhood Vaccines: Evidence bearing on causality. Washington, DC: National Academy Press, 1994:118-186
2. France EK, Glanz J, Xu S, et al. The risk of immune thrombocytopenic purpura following measles-mumps-rubella immunization in children. Pediatrics. 2008, in press
3. Kühne T, Imbach P, Bolton-Maggs, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358:2122-2125
4. Jadavji T, Scheifele D, Halperin S, et al. Thrombocytopenia after immunization of Canadian children, 1992-2001. Pediatr Infect Dis J. 2003;22(2):119-122
5. Rosthoj S, Hedlund-Treutiger I, Rajantie J, et al. Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: a prospective Nordic study of an un- selected cohort. J Pediatr. 2003;143(3):302-307
6. Kühne T, Buchanan, GR, Zimmerman S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood TCP Study Group. J Pediatr. 2003;143(5):605-608
7. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink Project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997;99(6):765-773
8. Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology. 2005;16(3):336-341
9. Kramarz P, France EK, DeStefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J. 2001;20(4):410-416
10. Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001;345(9):656-661
11. Ehresman K, Lynfield R, Danila R, et al. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. Mortal Morbid Wkly Rep. 1999;48(27):577-581
12. Food and Drug Administration, Centers for Disease Control and Prevention. Guillain-Barre syndrome among recipients of Men- actra Meningococcal conjugate vaccine-United States, June-July 2005. Mortal Morbid Wkly Rep. 2005;54(40):1023-1025
13. United States Food and Drug Administration. Law Strengthens FDA. Available at: www.fda.gov/oc/initiatives/advance/ fdaaa.html. Accessed December 27, 2007
14. Csizmadi I, Collet J, Boivin J. Bias and confounding in pharmacoepidemiology. In: Strom BL ed. Pharmacoepidemiology. Chichester, England: John Wiley and Sons, 2005:791-810
15. Miller E, Waight P, Farrington P, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001;84(3):227-229
16. Dayan D, Redd S, Rota P, et al. Measles-United States, 2005. Morbid Mortal Wkly Rep. 2006;55(50):1348-1351
17. Dabbagh A, Gacic-Dobo M, Wolfson L, et al. Progress in global measles control and mortality reduction., 2000-2006. Mortal Morbid Wkly Rep. 2007;56(47):1237-1241
18. Orenstein WA, Papania ML, Wharton ME. Measles elimination in the United States. J Infect Dis. 2004;189(suppl l):Sl-3